172 related articles for article (PubMed ID: 22116990)
1. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.
Cvelich RG; Roberts SC; Brown JN
Ann Pharmacother; 2011 Dec; 45(12):1551-8. PubMed ID: 22116990
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
Guazzi M; Vicenzi M; Arena R; Guazzi MD
Circ Heart Fail; 2011 Jan; 4(1):8-17. PubMed ID: 21036891
[TBL] [Abstract][Full Text] [Related]
3. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.
Zhuang XD; Long M; Li F; Hu X; Liao XX; Du ZM
Int J Cardiol; 2014 Apr; 172(3):581-7. PubMed ID: 24534379
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
5. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
7. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
[TBL] [Abstract][Full Text] [Related]
8. Acute and long-term efficacy and safety of sildenafil for the treatment of chronic thromboembolic pulmonary hypertension in a heart transplant recipient.
Zacà V; Padeletti M; Pagliaro A; Furiozzi F; Mondillo S; Favilli R
Pharmacology; 2011; 87(1-2):24-7. PubMed ID: 21178386
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil for pulmonary hypertension.
Lee AJ; Chiao TB; Tsang MP
Ann Pharmacother; 2005 May; 39(5):869-84. PubMed ID: 15827074
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
11. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
Guazzi M; Vicenzi M; Arena R
Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
[TBL] [Abstract][Full Text] [Related]
13. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
15. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
Azzouni F; Abu samra K
J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Varma A; Shah KB; Hess ML
Congest Heart Fail; 2012; 18(4):229-33. PubMed ID: 22507298
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute.
Potter BJ; White M; Carrier M; Pellerin M; L'Allier PL; Pelletier GB; Racine N; Ducharme A
Can J Cardiol; 2012; 28(1):69-73. PubMed ID: 22129489
[TBL] [Abstract][Full Text] [Related]
18. Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction.
Brown DA; Kyle JA; Ferrill MJ
Ann Pharmacother; 2009 Jul; 43(7):1275-85. PubMed ID: 19509350
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Lewis GD; Lachmann J; Camuso J; Lepore JJ; Shin J; Martinovic ME; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Jan; 115(1):59-66. PubMed ID: 17179022
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibitors in Raynaud's phenomenon.
Levien TL
Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
